The Zhitong Finance App learned that Yasheng Pharmaceutical (06855.HK) announced today that the company's two original Class 1 new drugs have been successfully included in the 2026 National Medical Insurance Drug List. Among them, Risentol® (resatocla) was first introduced through negotiations, and Nellick® (olevatinib) was successfully renewed through renegotiation. Up to now, all approved indications for both products have been included in the national medical insurance drug catalogue.

Zhitongcaijing · 3d ago
The Zhitong Finance App learned that Yasheng Pharmaceutical (06855.HK) announced today that the company's two original Class 1 new drugs have been successfully included in the 2026 National Medical Insurance Drug List. Among them, Risentol® (resatocla) was first introduced through negotiations, and Nellick® (olevatinib) was successfully renewed through renegotiation. Up to now, all approved indications for both products have been included in the national medical insurance drug catalogue.